Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/23550
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2021-12-24T08:34:27Z-
dc.date.available2021-12-24T08:34:27Z-
dc.date.issued2009-
dc.identifier.citationAskari, H. vd. (2009). "Carvedilol therapy in pediatric patients with dilated cardiomyopathy". Turkish Journal of Pediatrics, 51(1), 22-27.tr_TR
dc.identifier.issn00414301-
dc.identifier.urihttp://hdl.handle.net/11452/23550-
dc.description.abstractCarvedilol reduces mortality and hospitalization in adults with congestive heart failure. Limited information is available about its use in children. The objective of this study was to determine the dosing, efficacy and side effects of carvedilol for the management of dilated cardiomyopathy in children. Sixteen children with idiopathic dilated cardiomyopathy, aged 7 months to 138 months and with an ejection fraction less than 40%, were treated with carvedilol. The average initial dose was 0.1 mg/kg/day and it was uptitrated to 0.4 mg/kg/day. After six months on carvedilol, there were improvements in clinical scoring system from an average of 2.94 to 2.50 (p<0.05), in mean fractional shortening from 17.2 +/- 6.1% to 22.7 +/- 5.1% (p<0.05), and in ejection fraction from 35.2 6.8% to 43.1 +/- 11.2% (p<0.05). No side effect was observed during the study period. Two patients died due to serious infection. Carvedilol in addition to standard therapy for dilated cardiomyopathy in children improves cardiac function and symptoms. It is well tolerated, with minimal adverse effects, but close monitoring is necessary.en_US
dc.language.isoenen_US
dc.publisherTürk Pediatri Dergisitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCarvedilolen_US
dc.subjectChildrenen_US
dc.subjectDilated cardiomyopathyen_US
dc.subjectCongestive-heart-failureen_US
dc.subjectDouble-blinden_US
dc.subjectChildrenen_US
dc.subjectPediatricsen_US
dc.subject.meshAdrenergic beta-antagonistsen_US
dc.subject.meshCarbazolesen_US
dc.subject.meshCardiomyopathy, dilateden_US
dc.subject.meshChilden_US
dc.subject.meshChild, preschoolen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshPropanolaminesen_US
dc.titleCarvedilol therapy in pediatric patients with dilated cardiomyopathyen_US
dc.typeArticletr_TR
dc.identifier.wos000264733700005tr_TR
dc.identifier.scopus2-s2.0-65649142978tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.tr_TR
dc.identifier.startpage22tr_TR
dc.identifier.endpage27tr_TR
dc.identifier.volume51tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalTurkish Journal of Pediatricsen_US
dc.contributor.buuauthorAskari, Hülya-
dc.contributor.buuauthorSemizel, Evren-
dc.contributor.buuauthorBostan, Özlem Mehtap-
dc.contributor.buuauthorÇil, Ergün-
dc.contributor.researcheridAAG-9324-2021tr_TR
dc.contributor.researcheridAAH-3865-2021tr_TR
dc.indexed.trdizinTrDizintr_TR
dc.identifier.pubmed19378887tr_TR
dc.subject.wosPediatricsen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubmeden_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid26537185400tr_TR
dc.contributor.scopusid12646191300tr_TR
dc.contributor.scopusid8676936500tr_TR
dc.contributor.scopusid35587943300tr_TR
dc.subject.scopusRestrictive Cardiomyopathy; Heart Failure; Heart Right Ventricle Dysplasiaen_US
dc.subject.emtreeAcetylsalicylic aciden_US
dc.subject.emtreeCarvedilolen_US
dc.subject.emtreeDigoxinen_US
dc.subject.emtreeDipeptidyl carboxypeptidase inhibitoren_US
dc.subject.emtreeFurosemideen_US
dc.subject.emtreeBeta adrenergic receptor blocking agenten_US
dc.subject.emtreeCarbazole derivativeen_US
dc.subject.emtreeCarvedilolen_US
dc.subject.emtreePropanolamine derivativeen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBlood pressure measurementen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeCongestive cardiomyopathyen_US
dc.subject.emtreeDrug dose titrationen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug safetyen_US
dc.subject.emtreeDrug tolerabilityen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHeart functionen_US
dc.subject.emtreeHeart left ventricle ejection fractionen_US
dc.subject.emtreeHeart rateen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfanten_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeUnspecified side effecten_US
dc.subject.emtreePreschool childen_US
Appears in Collections:Scopus
TrDizin
Web of Science

Files in This Item:
File Description SizeFormat 
Askari_vd_2009.pdf214.48 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons